Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) EBIT (2020 - 2025)

Historic EBIT for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to -$15.1 million.

  • Barinthus Biotherapeutics' EBIT fell 6061.83% to -$15.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$82.4 million, marking a year-over-year decrease of 2758.64%. This contributed to the annual value of -$68.0 million for FY2024, which is 1900.04% up from last year.
  • Latest data reveals that Barinthus Biotherapeutics reported EBIT of -$15.1 million as of Q3 2025, which was down 6061.83% from -$23.3 million recorded in Q2 2025.
  • In the past 5 years, Barinthus Biotherapeutics' EBIT registered a high of $13.2 million during Q2 2022, and its lowest value of -$26.3 million during Q2 2023.
  • Moreover, its 5-year median value for EBIT was -$16.8 million (2021), whereas its average is -$13.7 million.
  • Its EBIT has fluctuated over the past 5 years, first skyrocketed by 23070.81% in 2022, then plummeted by 338501.53% in 2023.
  • Quarter analysis of 5 years shows Barinthus Biotherapeutics' EBIT stood at -$16.7 million in 2021, then crashed by 50.55% to -$25.1 million in 2022, then increased by 20.34% to -$20.0 million in 2023, then dropped by 17.02% to -$23.4 million in 2024, then skyrocketed by 35.59% to -$15.1 million in 2025.
  • Its EBIT was -$15.1 million in Q3 2025, compared to -$23.3 million in Q2 2025 and -$20.6 million in Q1 2025.